A Phase II Clinical Trial of Recombinant Interferon-γ on Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) have attracted considerable interest both in Japan and abroad since the concept was first proposed by the FAB group . However, effective methods of treatment have still not been established, except for bone marrow transplantation [2, 3]. Although the etiology of MDS is unclear, it is assumed that an abnormality at the pluripotent hematopoietic stem cell level is involved, and an ideal method of treatment appears to be replacement of the hematopoietic system with hematopoietic stem cells of healthy donors, i.e., allogeneic bone marrow transplantation. However, bone marrow transplantation is indicated only for young patients with matched bone marrow donors [3, 4]. Since MDS are prevalent in middle-aged or older patients, these patients cannot be considered candidates for bone marrow transplantation.
KeywordsFatigue Toxicity Europe Lymphoma Leukemia
Unable to display preview. Download preview PDF.
- 3.Tricot G, Boogaerts MA, Verwilghen RL (1986) Treatment of patients with myelodysplastic syndromes. A review. Scand J Haematol 36 [Suppl 451: 121–127Google Scholar
- 5.Yoshida Y, Oguma S, Yamagishi M, Uchino H, Maekawa T (1988) Prednisolone la-hydroxyvitamin D3 and androgens in the management of patients with refractory anemias. Myelodysplastic Syndromes Pathophysiology and treatment. In: Uchino H, Takaku F, Yoshida Y (eds) Elsevier, Amsterdam, pp 189–202Google Scholar
- 7.Yoshida Y, Sakota H, Ohmori S, Tohyama K, Ueda T, Ueda Y, Uchino H (1987) Marrow culture studies of myelodysplastic syndromes ( MDS ). Exp HematoI 15: 568Google Scholar